Lanraplenib

N/A

Report date: 2025/02/03 20:00:54
NME

Base Information

Drug NameLanraplenib
Drug Alias NameGS-SYKGS-SYK-succinatelanraplenib succinateGS-9876
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSpleen tyrosine kinase inhibitors
TargetsSpleen tyrosine kinase
Therapy Area/IndicationsInflammationLupus Erythematosus, CutaneousGlomerulonephritis, Membranous +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBulgariaCanada +[12] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGilead Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesIgnota Labs LtdGilead Sciences IncKronos Bio Inc
Active IndicationsN/A
Inactive IndicationsInflammationLupus Erythematosus, CutaneousGlomerulonephritis, Membranous +[6] 

Other Information

ATC CodeN/A
Related LinksN/A